The pan-TRK Inhibitor GNF5837 Inhibits Cell Viability and Akt and MAPK Signaling in Human Neuroendocrine GOT1 Tumor Cells

#874

Introduction: The tropomyosin receptor kinase family (TRKA, TRKB, TRKC) effects tumor cell growth in various models. Recent preclinical studies in neuroendocrine carcinoma of the lung cell lines have shown that Trk receptors might be a therapeutic target for neuroendocrine neoplasias.

Aim(s): Therefore, we investigated the antitumoral activity of the pan-Trk inhibitor GNF5837 (Tocris Bioscience) in different human neuroendocrine tumor (NET) cell lines.

Materials and methods: Human neuroendocrine pancreatic BON1 cells, bronchopulmonary H727 cells and midgut GOT1 cells were treated with different concentrations of GNF5837 (0.1 nM – 500nM) and the effects on cell viability (Cell Titer 96 Proliferation Assay, Promega) and signaling pathways (Western Blot analysis) were examined.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Heinzle V, Reuther C, Spöttl G, Maurer J, Göke B,

Keywords: neuroendocrine tumor, trk receptor,